Prospective close monitoring of the effect of vascular-targeted photodynamic therapy and high intensity focused ultrasound of localized prostate cancer by multiparametric magnetic resonance imaging
World Journal of Urology · 2024
DOI: 10.1007/s00345-024-05143-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, 2024. Verfasst von Olga Solyanik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Die Radiologie München, Munich, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Photochemotherapy, Multiparametric Magnetic Resonance Imaging. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The aim of this study is to describe the anatomical and functional changes observed in multiparametric magnetic resonance imaging (mpMRI) during follow-up after focal therapy (FT) for localized prostate cancer (PCa). MATERIALS AND METHODS: In this prospective study, we analyzed pre- and postoperatively acquired mpMRI of 10 patients after FT (7 days; 3, 6, 9, 12 months). 7/10 (70%) patients underwent vascular-targeted photodynamic therapy (VTP). 3/10 (30%) patients underwent high-intensity focused ultrasound (HIFU). MpMR image analysis was performed using a semi-automatic software for segmentation of the prostate gland (PG) and tumor zones. Signal intensities (SI) of T2-weighted (T2w), T1-weighted (T1w),diffusion-weighted (DWI) and dynamic contrast-enhanced (DCE) images as well as volumes of the prostate gland (PGV) and tumor volumes (TV) were evaluated at each time point. RESULTS: The results showed a significant increase of PGV 7 days after FT (p = 0.042) and a significant reduction of PGV between 7 days and 6, 9 and 12 months after FT (p < 0.001). The TV increased significantly 7 days after FT (p < 0.001) and decreased significantly between 7 days and 12 months after FT (p < 0.001). There was a significant increase in SI of the ADC in the ablation zone after 6, 9 and 12 months after FT (p < 0.001). 1/9 patients (11%) had recurrent tumor on rebiopsy characterized as a a small focal lesion on mpMRI with strong diffusion restriction (low SI on ADC map and high SI on b-value DWI). CONCLUSION: MpMRI is able to represent morphologic changes of the ablated zone after FT and might be helpful to detect recurrent tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Die Radiologie München, Munich, Germany.
- Department of Urology, LMU Klinikum, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany.
- Department of Radiology, LMU Klinikum, Ludwig-Maximilians-University Munich, Germany, Munich.
- Department of Urology, LMU Klinikum, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany. maria.apfelbeck@med.uni-muenchen.de.
Zitieren
APA
Solyanik, O., Chaloupka, M., Clevert, D. A., Schmidt, V. F., Ingenerf, M., Kazmierczak, P., Stief, C. G., Ricke, J., & Apfelbeck, M. (2024). Prospective close monitoring of the effect of vascular-targeted photodynamic therapy and high intensity focused ultrasound of localized prostate cancer by multiparametric magnetic resonance imaging. World Journal of Urology. https://doi.org/10.1007/s00345-024-05143-6
Vancouver
Solyanik O, Chaloupka M, Clevert DA, Schmidt VF, Ingenerf M, Kazmierczak P, et al. Prospective close monitoring of the effect of vascular-targeted photodynamic therapy and high intensity focused ultrasound of localized prostate cancer by multiparametric magnetic resonance imaging. World Journal of Urology. 2024. doi:10.1007/s00345-024-05143-6
BibTeX
@article{Solyanik2024,
author = {Solyanik, Olga and Chaloupka, Michael and Clevert, Dirk-André and Schmidt, Vanessa F and Ingenerf, Maria and Kazmierczak, Philipp and Stief, Christian G and Ricke, Jens and Apfelbeck, Maria},
title = {Prospective close monitoring of the effect of vascular-targeted photodynamic therapy and high intensity focused ultrasound of localized prostate cancer by multiparametric magnetic resonance imaging},
journal = {World Journal of Urology},
year = {2024},
doi = {10.1007/s00345-024-05143-6}
}
EUVIMED